Lupus & antiphospholipid syndrome
Real-world glucocorticoid prescription patterns in patients with lupus nephritis: A retrospective study using a healthcare insurance claims database
Authors' conclusion
Approximately half of the patients with LN were prescribed GC ≤5.0 mg/day within 1.5 years after starting the initial therapy.
Study context
- Population
- Patients with lupus nephritis (LN) starting initial therapy (oral glucocorticoids (GC) ≥20.0 mg/day prednisolone equivalent or IV GC pulse), JMDC claims database, Japan, May 2016–March 2023
- Participants
- 295 patients
- Exposure
- Dose reduction target achieved vs non-achieved
- Outcome
- Proportion of patients prescribed oral GC ≤5.0 mg/day
- Follow-up
- Day 540
Methodological detailshealthcare insurance claims database (JMDC), descriptive analyses
- Healthcare insurance claims database (JMDC)
- Descriptive analyses
Main finding
As reported in the abstract
Patients prescribed GC ≤5.0 mg/day
Overall population, Day 540
48.1%
Overall population, Day 1
1.0%
Observational data: associations, not effects.
Further findings
Patients with GC ≤7.5 mg/day · Day 180
Baseline concomitant immunosuppressants
MMF
TAC
- Baseline concomitant immunosuppressants — Overall: Mycophenolate mofetil (MMF)
- 41.7%
- Baseline concomitant immunosuppressants — Overall: Tacrolimus (TAC)
- 16.9%
Mean oral GC baseline dose, overall population
- Mean oral GC baseline dose (mg/day)
- 36.1
Original publication
Real-world glucocorticoid prescription patterns in patients with lupus nephritis: A retrospective study using a healthcare insurance claims database. Lupus. Published 19 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →